Cargando…

A Selective Mineralocorticoid Receptor Blocker, Esaxerenone, Attenuates Vascular Dysfunction in Diabetic C57BL/6 Mice

Aims: Pharmacological blockade of mineralocorticoid receptors (MRs) is a potential therapeutic approach to reduce cardiovascular complications since MRs play a crucial role in cardiovascular regulation. Recent studies suggest that MR antagonists affect several extrarenal tissues, including vessel fu...

Descripción completa

Detalles Bibliográficos
Autores principales: Munkhjargal, Uugantsetseg, Fukuda, Daiju, Ganbaatar, Byambasuren, Suto, Kumiko, Matsuura, Tomomi, Ise, Takayuki, Kusunose, Kenya, Yamaguchi, Koji, Yagi, Shusuke, Yamada, Hirotsugu, Soeki, Takeshi, Wakatsuki, Tetsuzo, Sata, Masataka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japan Atherosclerosis Society 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067342/
https://www.ncbi.nlm.nih.gov/pubmed/35732424
http://dx.doi.org/10.5551/jat.63382
_version_ 1785018443389468672
author Munkhjargal, Uugantsetseg
Fukuda, Daiju
Ganbaatar, Byambasuren
Suto, Kumiko
Matsuura, Tomomi
Ise, Takayuki
Kusunose, Kenya
Yamaguchi, Koji
Yagi, Shusuke
Yamada, Hirotsugu
Soeki, Takeshi
Wakatsuki, Tetsuzo
Sata, Masataka
author_facet Munkhjargal, Uugantsetseg
Fukuda, Daiju
Ganbaatar, Byambasuren
Suto, Kumiko
Matsuura, Tomomi
Ise, Takayuki
Kusunose, Kenya
Yamaguchi, Koji
Yagi, Shusuke
Yamada, Hirotsugu
Soeki, Takeshi
Wakatsuki, Tetsuzo
Sata, Masataka
author_sort Munkhjargal, Uugantsetseg
collection PubMed
description Aims: Pharmacological blockade of mineralocorticoid receptors (MRs) is a potential therapeutic approach to reduce cardiovascular complications since MRs play a crucial role in cardiovascular regulation. Recent studies suggest that MR antagonists affect several extrarenal tissues, including vessel function. We investigated the effect of a novel nonsteroidal selective MR blocker, esaxerenone, on diabetes-induced vascular dysfunction. Methods: Diabetes was induced by a single dose of streptozotocin in 8-week-old male C57BL/6 mice. Esaxerenone (3 mg/kg/day) or a vehicle was administered by gavage to diabetic mice for 3 weeks. Metabolic parameters, plasma aldosterone levels, and parameters related to renal function were measured. Endothelium-dependent or -independent vascular responses of the aortic segments were analyzed with acetylcholine or sodium nitroprusside, respectively. Human umbilical vein endothelial cells (HUVECs) were used for the in vitro study. Results: Induction of diabetes elevated plasma aldosterone level (P<0.05) and impaired endothelium-dependent vascular relaxation (P<0.05). The administration of esaxerenone ameliorated the endothelial dysfunction (P<0.01) without the alteration of metabolic parameters, blood pressure, and renal function. Esaxerenone improved the eNOS(Ser1177) phosphorylation in the aorta obtained from diabetic mice (P<0.05) compared with that in the vehicle-treated group. Furthermore, a major MR agonist, aldosterone, decreased eNOS(Ser1177) phosphorylation and increased eNOS(Thr495) phosphorylation in HUVECs, which recovered with esaxerenone. Esaxerenone ameliorated the endothelium-dependent vascular relaxation caused by aldosterone in the aortic segments obtained from C57BL/6 mice (P<0.001). Conclusion: Esaxerenone attenuates the development of diabetes-induced endothelial dysfunction in mice. These results suggest that esaxerenone has potential vascular protective effects in individuals with diabetes.
format Online
Article
Text
id pubmed-10067342
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Japan Atherosclerosis Society
record_format MEDLINE/PubMed
spelling pubmed-100673422023-04-04 A Selective Mineralocorticoid Receptor Blocker, Esaxerenone, Attenuates Vascular Dysfunction in Diabetic C57BL/6 Mice Munkhjargal, Uugantsetseg Fukuda, Daiju Ganbaatar, Byambasuren Suto, Kumiko Matsuura, Tomomi Ise, Takayuki Kusunose, Kenya Yamaguchi, Koji Yagi, Shusuke Yamada, Hirotsugu Soeki, Takeshi Wakatsuki, Tetsuzo Sata, Masataka J Atheroscler Thromb Original Article Aims: Pharmacological blockade of mineralocorticoid receptors (MRs) is a potential therapeutic approach to reduce cardiovascular complications since MRs play a crucial role in cardiovascular regulation. Recent studies suggest that MR antagonists affect several extrarenal tissues, including vessel function. We investigated the effect of a novel nonsteroidal selective MR blocker, esaxerenone, on diabetes-induced vascular dysfunction. Methods: Diabetes was induced by a single dose of streptozotocin in 8-week-old male C57BL/6 mice. Esaxerenone (3 mg/kg/day) or a vehicle was administered by gavage to diabetic mice for 3 weeks. Metabolic parameters, plasma aldosterone levels, and parameters related to renal function were measured. Endothelium-dependent or -independent vascular responses of the aortic segments were analyzed with acetylcholine or sodium nitroprusside, respectively. Human umbilical vein endothelial cells (HUVECs) were used for the in vitro study. Results: Induction of diabetes elevated plasma aldosterone level (P<0.05) and impaired endothelium-dependent vascular relaxation (P<0.05). The administration of esaxerenone ameliorated the endothelial dysfunction (P<0.01) without the alteration of metabolic parameters, blood pressure, and renal function. Esaxerenone improved the eNOS(Ser1177) phosphorylation in the aorta obtained from diabetic mice (P<0.05) compared with that in the vehicle-treated group. Furthermore, a major MR agonist, aldosterone, decreased eNOS(Ser1177) phosphorylation and increased eNOS(Thr495) phosphorylation in HUVECs, which recovered with esaxerenone. Esaxerenone ameliorated the endothelium-dependent vascular relaxation caused by aldosterone in the aortic segments obtained from C57BL/6 mice (P<0.001). Conclusion: Esaxerenone attenuates the development of diabetes-induced endothelial dysfunction in mice. These results suggest that esaxerenone has potential vascular protective effects in individuals with diabetes. Japan Atherosclerosis Society 2023-04-01 2022-06-23 /pmc/articles/PMC10067342/ /pubmed/35732424 http://dx.doi.org/10.5551/jat.63382 Text en 2023 Japan Atherosclerosis Society https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.http://creativecommons.org/licenses/by-nc-sa/4.0/ (https://creativecommons.org/licenses/by-nc-sa/4.0/)
spellingShingle Original Article
Munkhjargal, Uugantsetseg
Fukuda, Daiju
Ganbaatar, Byambasuren
Suto, Kumiko
Matsuura, Tomomi
Ise, Takayuki
Kusunose, Kenya
Yamaguchi, Koji
Yagi, Shusuke
Yamada, Hirotsugu
Soeki, Takeshi
Wakatsuki, Tetsuzo
Sata, Masataka
A Selective Mineralocorticoid Receptor Blocker, Esaxerenone, Attenuates Vascular Dysfunction in Diabetic C57BL/6 Mice
title A Selective Mineralocorticoid Receptor Blocker, Esaxerenone, Attenuates Vascular Dysfunction in Diabetic C57BL/6 Mice
title_full A Selective Mineralocorticoid Receptor Blocker, Esaxerenone, Attenuates Vascular Dysfunction in Diabetic C57BL/6 Mice
title_fullStr A Selective Mineralocorticoid Receptor Blocker, Esaxerenone, Attenuates Vascular Dysfunction in Diabetic C57BL/6 Mice
title_full_unstemmed A Selective Mineralocorticoid Receptor Blocker, Esaxerenone, Attenuates Vascular Dysfunction in Diabetic C57BL/6 Mice
title_short A Selective Mineralocorticoid Receptor Blocker, Esaxerenone, Attenuates Vascular Dysfunction in Diabetic C57BL/6 Mice
title_sort selective mineralocorticoid receptor blocker, esaxerenone, attenuates vascular dysfunction in diabetic c57bl/6 mice
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067342/
https://www.ncbi.nlm.nih.gov/pubmed/35732424
http://dx.doi.org/10.5551/jat.63382
work_keys_str_mv AT munkhjargaluugantsetseg aselectivemineralocorticoidreceptorblockeresaxerenoneattenuatesvasculardysfunctionindiabeticc57bl6mice
AT fukudadaiju aselectivemineralocorticoidreceptorblockeresaxerenoneattenuatesvasculardysfunctionindiabeticc57bl6mice
AT ganbaatarbyambasuren aselectivemineralocorticoidreceptorblockeresaxerenoneattenuatesvasculardysfunctionindiabeticc57bl6mice
AT sutokumiko aselectivemineralocorticoidreceptorblockeresaxerenoneattenuatesvasculardysfunctionindiabeticc57bl6mice
AT matsuuratomomi aselectivemineralocorticoidreceptorblockeresaxerenoneattenuatesvasculardysfunctionindiabeticc57bl6mice
AT isetakayuki aselectivemineralocorticoidreceptorblockeresaxerenoneattenuatesvasculardysfunctionindiabeticc57bl6mice
AT kusunosekenya aselectivemineralocorticoidreceptorblockeresaxerenoneattenuatesvasculardysfunctionindiabeticc57bl6mice
AT yamaguchikoji aselectivemineralocorticoidreceptorblockeresaxerenoneattenuatesvasculardysfunctionindiabeticc57bl6mice
AT yagishusuke aselectivemineralocorticoidreceptorblockeresaxerenoneattenuatesvasculardysfunctionindiabeticc57bl6mice
AT yamadahirotsugu aselectivemineralocorticoidreceptorblockeresaxerenoneattenuatesvasculardysfunctionindiabeticc57bl6mice
AT soekitakeshi aselectivemineralocorticoidreceptorblockeresaxerenoneattenuatesvasculardysfunctionindiabeticc57bl6mice
AT wakatsukitetsuzo aselectivemineralocorticoidreceptorblockeresaxerenoneattenuatesvasculardysfunctionindiabeticc57bl6mice
AT satamasataka aselectivemineralocorticoidreceptorblockeresaxerenoneattenuatesvasculardysfunctionindiabeticc57bl6mice
AT munkhjargaluugantsetseg selectivemineralocorticoidreceptorblockeresaxerenoneattenuatesvasculardysfunctionindiabeticc57bl6mice
AT fukudadaiju selectivemineralocorticoidreceptorblockeresaxerenoneattenuatesvasculardysfunctionindiabeticc57bl6mice
AT ganbaatarbyambasuren selectivemineralocorticoidreceptorblockeresaxerenoneattenuatesvasculardysfunctionindiabeticc57bl6mice
AT sutokumiko selectivemineralocorticoidreceptorblockeresaxerenoneattenuatesvasculardysfunctionindiabeticc57bl6mice
AT matsuuratomomi selectivemineralocorticoidreceptorblockeresaxerenoneattenuatesvasculardysfunctionindiabeticc57bl6mice
AT isetakayuki selectivemineralocorticoidreceptorblockeresaxerenoneattenuatesvasculardysfunctionindiabeticc57bl6mice
AT kusunosekenya selectivemineralocorticoidreceptorblockeresaxerenoneattenuatesvasculardysfunctionindiabeticc57bl6mice
AT yamaguchikoji selectivemineralocorticoidreceptorblockeresaxerenoneattenuatesvasculardysfunctionindiabeticc57bl6mice
AT yagishusuke selectivemineralocorticoidreceptorblockeresaxerenoneattenuatesvasculardysfunctionindiabeticc57bl6mice
AT yamadahirotsugu selectivemineralocorticoidreceptorblockeresaxerenoneattenuatesvasculardysfunctionindiabeticc57bl6mice
AT soekitakeshi selectivemineralocorticoidreceptorblockeresaxerenoneattenuatesvasculardysfunctionindiabeticc57bl6mice
AT wakatsukitetsuzo selectivemineralocorticoidreceptorblockeresaxerenoneattenuatesvasculardysfunctionindiabeticc57bl6mice
AT satamasataka selectivemineralocorticoidreceptorblockeresaxerenoneattenuatesvasculardysfunctionindiabeticc57bl6mice